Stage
No active trials
Next date
None yet
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- Blocks the effect of angiotensin II, a hormone that narrows blood vessels. Lowers blood pressure.-sartan: angiotensin II receptor antagonists WHO name stem
- How it’s given
- “First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration”In the company’s words, NCT04856969 on ClinicalTrials.gov
- Main trialPhase 1
- “To evaluate the interaction between two investigational products by comparing and analyzing pharmacokinetic interactions and safety in steady state after multiple oral administration of ATB-1011 or ATB-1012 alone or in combination in healthy adult volunteers.”In the company’s words, NCT04856969 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 4 May 2021 | Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers | |
| Phase 4Authorised | not given | Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026